The isoxazol-3-one tautomer of the bicyclic isoxazole, 5, 6, 7, 8-tetrahydro-4 H-isoxazolo [4, 5-d] azepin-3-ol (THAZ), has previously been shown to be a weak GABAA and glycine receptor antagonist. In the present study, the potential in this scaffold has been explored